Circulating miRNA in Atherosclerosis: A Clinical Biomarker and Early Diagnostic Tool

Sharma, Ashish Ranjan; Sharma, Garima; Bhattacharya, Manojit; Lee, Sang-Soo; Chakraborty, Chiranjib

doi:10.2174/1566524021666210315124438

Cited by 25 publications

(18 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, given the links between dyslipidemia, inflammation, and atherosclerosis, several miRNAs (i.e., miR-27a/b, miR-146a, miR-125a-5p, miR-155, miR-301b, miR-302a) have demonstrated their role in lipid metabolism. They seem to be involved in the absorption, esterification, and efflux of cholesterol, as well as in the process of foam cell development, reducing their number [ 111 , 112 , 113 ].…”

Section: Assessing Cardiovascular Risk In Ramentioning

confidence: 99%

Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy

Popescu

Rezuş

Bădescu

et al. 2023

Life

View full text Add to dashboard Cite

Rheumatoid arthritis (RA), one of the most common of the chronic inflammatory autoimmune diseases (CIADs), is recognized as an independent cardiovascular risk factor. Traditional risk factors such as smoking, arterial hypertension, dyslipidemia, insulin resistance, and obesity are frequently found in RA. Given the increased risk of mortality and morbidity associated with cardiovascular disease (CVD) in RA patients, screening for risk factors is important. Moreover, there is a need to identify potential predictors of subclinical atherosclerosis. Recent studies have shown that markers such as serum homocysteine, asymmetric dimethylarginine, or carotid intima–media thickness (cIMT) are correlated with cardiovascular risk. Although RA presents a cardiovascular risk comparable to that of diabetes, it is not managed as well in terms of acute cardiovascular events. The introduction of biological therapy has opened new perspectives in the understanding of this pathology, confirming the involvement and importance of the inflammatory markers, cytokines, and the immune system. In addition to effects in inducing remission and slowing disease progression, most biologics have demonstrated efficacy in reducing the risk of major cardiovascular events. Some studies have also been conducted in patients without RA, with similar results. However, early detection of atherosclerosis and the use of targeted therapies are the cornerstone for reducing cardiovascular risk in RA patients.

show abstract

Section: Assessing Cardiovascular Risk In Ramentioning

confidence: 99%

Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy

Popescu

Rezuş

Bădescu

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

“…Concerning miR-29b, it was detected in human serum and differentially expressed in the blood of patients with neurodegenerative diseases, including Alzheimer’s disease (AD), in which it constitutes a potential biomarker for AD treatment [ 104 ]. Furthermore, circulating miR-29b was reported to increase with aging, which often constitutes a comorbidity in breast cancer, and seems to be correlated with early atherosclerosis [ 105 ], muscle atrophy [ 106 ], changes in cortical metabolism [ 107 ], and osteoporosis [ 108 ].…”

Section: Circulating Mir-29bmentioning

confidence: 99%

Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches

2022

View full text Add to dashboard Cite

The miR-29 family comprises miR-29a, miR-29b, and miR-29c, and these molecules play crucial and partially overlapped functions in solid tumors, in which the different isoforms are variously de-regulated and mainly correlated with tumor suppression. miR-29b is the most expressed family member in cancer, in which it is involved in regulating gene expression at both transcriptional and post-transcriptional levels. This review focuses on the role of miR-29b in breast cancer, in which it plays a controversial role as tumor suppressor or onco-miRNA. Here we have highlighted the dual effect of miR-29b on breast tumor features, which depend on the prevailing function of this miRNA, on the mature miR-29b evaluated, and on the breast tumor characteristics. Remarkably, the analyzed miR-29b form emerged as a crucial element in the results obtained by various research groups, as the most abundant miR-29b-3p and the less expressed miR-29b1-5p seem to play distinct roles in breast tumors with different phenotypes. Of particular interest are the data showing that miR-29b1-5p counteracts cell proliferation and migration and reduces stemness in breast tumor cells with a triple negative phenotype. Even if further studies are required to define exactly the role of each miR-29b, our review highlights its possible implication in phenotype-specific management of breast tumors.

show abstract

“…Studies indicate that many pathophysiological procedures for different diseases, such as cancer, hypertension, stroke, diabetes, and CHD, consist of various cellular pathways. [ 8 , 9 ] One of the vital mechanisms is miRNA regulation. [ 10 , 11 ] Studies show that miR-146a is involved in the process of CHD.…”

Section: Introductionmentioning

confidence: 99%

Association between microRNA-146a rs2910164 polymorphism and coronary heart disease: An updated meta-analysis

Bao¹,

Li²,

Wang³

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Coronary heart disease (CHD) is one of the manifestations of atherosclerosis with a high morbidity rate. MicroRNA (miRNA)-146a rs2910164, a single nucleotide polymorphism, is associated with the progression of CHD risk. However, the results are controversial and uncertain. Therefore, an updated meta-analysis was conducted to evaluate the association between rs2910164 and CHD susceptibility.Methods: PubMed, Cochrane Library, EMBASE, Web of Science, China's National Knowledge Infrastructure, VIP, and Wan fang were searched for the eligible articles until April 30, 2022. The odds ratios (ORs) with 95% confidence interval (CIs) were calculated to assess the correlation. Bonferroni correction was utilized between multiple comparisons. Trial sequential analysis was performed to measure the required information size and assess the reliability of the meta-analysis results.Results: A total of 18 eligible studies, including 6859 cases and 8469 controls, were analyzed in our meta-analysis. After Bonferroni correction, we found that the G allele at rs2910164 was associated with significantly decreased CHD risk in the allelic model (OR = 0.86), homozygous model (OR = 0.79), and heterozygous model (OR = 0.89) in total population. In the subgroup analysis, the subjects containing the G allele and GG genotype were associated with a lower risk of CHD in the Chinese population, not the GG + CG and CG genotype. In addition, under the allelic, homozygous, heterozygous, and dominant models, miR-146a rs2910164 was at lower CHD risk in the large size population except in the recessive model. Conclusion:These results show that miR-146a rs2910164 might be associated with lower CHD susceptibility.Abbreviations: CAD = coronary artery disease, CHD = coronary heart disease, CI = confidence interval, HWE = Hardy-Weinberg equilibrium, IRAK-1 = interleukin-1 receptor-associated kinase 1, miRNA = microRNA, NF-κB = nuclear factor Kappa B, RIS = required information size, SNP = single nucleotide polymorphism, TRAF-6 = tumor necrosis factor receptor-associated factor 6, TSA = trial sequential analysis.

show abstract

Circulating miRNA in Atherosclerosis: A Clinical Biomarker and Early Diagnostic Tool

Cited by 25 publications

References 94 publications

Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy

Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy

Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches

Association between microRNA-146a rs2910164 polymorphism and coronary heart disease: An updated meta-analysis

Contact Info

Product

Resources

About